Advancing Cell Therapy for Heart Failure: BioCardia Announces CardiAMP HF II Trial Begins with First Patient
BioCardia announced the enrollment of the first patient in their Phase 3 CardiAMP HF II clinical trial, which is evaluating their lead cell therapy for heart failure. This trial will assess the safety and effectiveness of the autologous cell therapy, which uses a patient’s own bone marrow cells delivered to the heart to potentially stimulate healing. The study builds on previous trials […]
BioCardia Completes Phase III Clinical Trial of Autologous Stem Cell Therapy for Ischemic Heart Failure
BioCardia, Inc., a leader in cellular therapies for cardiovascular diseases, has announced the completion of its pivotal Phase III trial for CardiAMP®, an autologous cell therapy designed to treat ischemic heart failure with reduced ejection fraction (HFrEF). This milestone marks the last patient follow-up in the double-blind, placebo-controlled trial, which aims to assess the safety […]